STIM (Neuronetics) 10-Year Sortino Ratio: N/A (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STIM Neuronetics Inc STIM
60 GF Score
Price $2.88
GF Value $1.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Neuronetics 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-07), Neuronetics's 10-Year Sortino Ratio is Not available.


Neuronetics  (NAS:STIM) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Neuronetics 10-Year Sortino Ratio Related Terms


STIM vs INFU, ELMD, LAB: 10-Year Sortino Ratio Comparison

For the Medical Devices subindustry, Neuronetics's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuronetics 10-Year Sortino Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Neuronetics's 10-Year Sortino Ratio falls into.


STIM
60GF Score
Neuronetics Inc STIM
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuronetics 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Neuronetics (STIM) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be overvalued. The current stock price of $2.88 is trading 61.8% above its estimated GF Value™ of $1.78. GuruFocus considers Neuronetics to be Significantly Overvalued.

Key valuation signals for STIM:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $1.78 vs. price of $2.88 (61.8% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the STIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuronetics Business Description

Other Exchanges NRC:Germany
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
60GF Score

Get the complete analysis for STIM

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.88
Price
$1.78
GF Value